Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
The U.S. Preventive Services Task Force (USPSTF) today released new recommendations for breast cancer screening.
The USPSTF recommends against routine screening mammography for women
age 40 to 49 years and encourages women to speak with their doctors
about their risk for breast cancer as well as the potential benefits and
harms of mammography.
Women aged 50 to 74 years should have mammography every two years.
The USPSTF reports that more evidence is needed to recommend for or
against screening mammography after age 74 years.
The complete guidelines, to be published in the Nov. 17 issue of the Annals of Internal Medicine, will be available online at www.annals.org.
Dana-Farber Cancer Institute breast cancer and prevention experts
feel it is important that women recognize that while mammography is not
perfect, it is the best breast cancer screening tool currently
available. Women are encouraged to speak with their primary care
providers to discuss their health history and their risk for breast
"There is no controversy over the fact that mammograms reduce breast
cancer deaths, but there has been ongoing concern about how mammograms
should be best used," said Judy Garber, MD, MPH, a breast oncologist and
director of the cancer risk and prevention clinic at Dana-Farber Cancer
Judy Garber, MD, MPH
"These new guidelines will force many groups to reevaluate their
recommendations, but we certainly don't want women and their physicians
to abandon mammography, which is an imperfect tool, but is the best
method we currently have to screen women at average risk of breast
Eric Winer, MD, director of the breast oncology center at
Dana-Farber, added that greater focus needs to be placed on ensuring
better access to the test.
"A major concern is that fully a third of women do not undergo any
form of mammographic screening. We need to work to make sure that all
women have access to mammography and take advantage of the benefits
associated with screening."
The USPSTF is an independent panel of private-sector experts in
prevention and primary care. It was first convened by the U.S. Public
Health Service in 1984, and since 1998 it has been sponsored by the
Agency for Healthcare Research and Quality. The USPSTF's mission is to
evaluate the benefits of individual services based on age, gender, and
risk factors for disease; make recommendations about which preventive
services should be incorporated routinely into primary medical care and
for which populations; and identify a research agenda for clinical
Dana-Farber Cancer Institute (www.dana-farber.org)
is a principal teaching affiliate of the Harvard Medical School and is
among the leading cancer research and care centers in the United States.
It is a founding member of the Dana-Farber/Harvard Cancer Center
(DF/HCC), designated a comprehensive cancer center by the National
Cancer Institute. It is the top ranked cancer center in New England,
according to U.S. News & World Report, and one of the
largest recipients among independent hospitals of National Cancer
Institute and National Institutes of Health grant funding